Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial

BACKGROUND: Cure rates for Hodgkin’s lymphoma are excellent, but excess short-term and long-term morbidities from treatment remain a concern. Immunotherapy targeting both tumor antigens and the immunosuppressive tumor microenvironment in children, adolescents, and young adults with Hodgkin’s lymphom...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochberg, Jessica, Basso, Jaclyn, Shi, Qiuhu, Klejmont, Liana, Flower, Allyson, Bortfeld, Kristina, Harrison, Lauren, van de Ven, Carmella, Moorthy, Chitti, Islam, Humayun, Gerard, Perry, Voss, Stephan, Cairo, Mitchell S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119160/
https://www.ncbi.nlm.nih.gov/pubmed/35584865
http://dx.doi.org/10.1136/jitc-2021-004445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119160/
https://www.ncbi.nlm.nih.gov/pubmed/35584865
http://dx.doi.org/10.1136/jitc-2021-004445

Ejemplares similares